BMI View: Multinational drugmakers with higher exposure to the US pharmaceutical market will outperform rivals with established presences in Western Europe and emerging markets. The former region is under pressure from austerity-induced medicine price cuts, and many markets will experience significant contractions in 2013. Meanwhile, the latter is seeing currency weakness and deepening industry-specific challenges, such as the bribery/corruption scandal in China. The US remains highly attractive due to the willingness of payers to reimburse patients for high-value patented pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: US$343.0bn in 2012 to US$342.6bn in 2013; -0.1% growth in local currency terms. Forecast slightly …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=117505.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/united-states-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment